ATLANTA, Nov. 4, 2015 /PRNewswire/ -- Alimera Sciences, Inc. ALIM (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a 36-month analysis of patients treated with ILUVIEN® has been accepted as a Late Breaking Development during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting 2015. The presentation, "Analysis of Diabetic Retinopathy Progression in Patients Treated with 0.2 microns/day Fluocinolone Acetonide Over 36 Months" by Charles C. Wykoff, M.D., Ph.D., Retina Consultants of Houston, is slated for November 14 at 9:21 a.m. at the Sands Expo/Venetian, Las Vegas.
The 2015 Retina Subspecialty Day provides a comprehensive and focused medical and surgical retina update for retina subspecialists, interested ophthalmologists, and ophthalmologists in training. The meeting focuses on up-to-date, clinically and scientifically relevant topics presented by an international group of respected retina specialists.
"We are very pleased the AAO scientific reviewers selected this analysis for presentation as a Late Breaking Development," said Dan Myers, Alimera president and chief executive officer.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alimera-sciences-announces-late-breaking-presentation-of-new-iluvien-analysis-during-retina-subspecialty-day-at-aao-annual-meeting-2015-300170110.html
SOURCE Alimera Sciences, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.